{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:16:19Z","timestamp":1792700179716,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41416-018-0020-2","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T13:24:08Z","timestamp":1521120248000},"page":"1042-1050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical pharmacodynamic\/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial"],"prefix":"10.1038","volume":"118","author":[{"given":"Michael L.","family":"Maitland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Janisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Karovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hoening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekman","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijith","family":"Munasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherrie","family":"Donawho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guinan K.","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"key":"20_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski, R. Jr Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol. Res. 103, 26\u201348 (2016).","journal-title":"Pharmacol. Res."},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","volume":"21","author":"P Wu","year":"2016","unstructured":"Wu, P., Nielsen, T. E. & Clausen, M. H. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug. Discov. Today 21, 5\u201310 (2016).","journal-title":"Drug. Discov. Today"},{"key":"20_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0065-230X(06)96008-4","volume":"96","author":"D Sarker","year":"2007","unstructured":"Sarker, D. & Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213\u2013268 (2007).","journal-title":"Adv. Cancer Res."},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.seminoncol.2016.06.001","volume":"43","author":"U Banerji","year":"2016","unstructured":"Banerji, U. & Workman, P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin. Oncol. 43, 436\u2013445 (2016).","journal-title":"Semin. Oncol."},{"key":"20_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127\u2013132 (2008).","journal-title":"Nat. Biotechnol."},{"key":"20_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1021\/acs.jcim.6b00122","volume":"56","author":"S Christmann-Franck","year":"2016","unstructured":"Christmann-Franck, S. et al. Unprecedentedly large-scale kinase inhibitor set enabling the accurate prediction of compound-kinase activities: a way toward selective promiscuity by design? J. Chem. Inf. Model. 56, 1654\u20131675 (2016).","journal-title":"J. Chem. Inf. Model."},{"key":"20_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046\u20131051 (2011).","journal-title":"Nat. Biotechnol."},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).","journal-title":"Sci. Transl. Med"},{"key":"20_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nbt.3367","volume":"34","author":"BA Kidd","year":"2016","unstructured":"Kidd, B. A. et al. Mapping the effects of drugs on the immune system. Nat. Biotechnol. 34, 47\u201354 (2016).","journal-title":"Nat. Biotechnol."},{"key":"20_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1124\/jpet.112.197087","volume":"343","author":"KB Glaser","year":"2012","unstructured":"Glaser, K. B. et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor\/platelet-derived growth factor receptor, and Src kinase families. J. Pharmacol. Exp. Ther. 343, 617\u2013627 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"20_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2174\/1568009615666150421110401","volume":"15","author":"S Sarvagalla","year":"2015","unstructured":"Sarvagalla, S. & Coumar, M. S. Structural biology insight for the design of sub-type selective Aurora kinase inhibitors. Curr. Cancer Drug Targets. 15, 375\u2013393 (2015).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"20_CR12","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1016\/j.bmcl.2012.03.035","volume":"22","author":"ML Curtin","year":"2012","unstructured":"Curtin, M. L. et al. Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorg. Med. Chem. Lett. 22, 3208\u20133212 (2012a).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"20_CR13","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1016\/j.bmcl.2012.05.067","volume":"22","author":"ML Curtin","year":"2012","unstructured":"Curtin, M. L. et al. Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. Bioorg. Med. Chem. Lett. 22, 4750\u20134755 (2012b).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"20_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-05-0359","volume":"5","author":"J Guo","year":"2006","unstructured":"Guo, J. et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol. Cancer Ther. 5, 1007\u20131013 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"20_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s10637-015-0242-6","volume":"33","author":"G Garcia-Manero","year":"2015","unstructured":"Garcia-Manero, G. et al. Phase 1 dose escalation trial of ilorasertib, a dual Aurora\/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest. New. Drugs. 33, 870\u2013880 (2015).","journal-title":"Invest. New. Drugs"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2307\/2532905","volume":"52","author":"J O\u2019Quigley","year":"1996","unstructured":"O\u2019Quigley, J. & Shen, L. Z. Continual reassessment method: a likelihood approach. Biometrics 52, 673\u2013684 (1996).","journal-title":"Biometrics"},{"key":"20_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1081\/BIP-100102497","volume":"10","author":"O Wang","year":"2000","unstructured":"Wang, O. & Faries, D. E. A two-stage dose selection strategy in phase I trials with wide dose ranges. J. Biopharm. Stat. 10, 319\u2013333 (2000).","journal-title":"J. Biopharm. Stat."},{"key":"20_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sim.4780141102","volume":"14","author":"SN Goodman","year":"1995","unstructured":"Goodman, S. N., Zahurak, M. L. & Piantadosi, S. Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14, 1149\u20131161 (1995).","journal-title":"Stat. Med."},{"key":"20_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/HYPERTENSIONAHA.112.191213","volume":"60","author":"RW Powers","year":"2012","unstructured":"Powers, R. W. et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 60, 239\u2013246 (2012).","journal-title":"Hypertension"},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/01.CIR.0000154900.76284.F6","volume":"111","author":"TG Pickering","year":"2005","unstructured":"Pickering, T. G. et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111, 697\u2013716 (2005).","journal-title":"Circulation"},{"key":"20_CR21","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","volume":"15","author":"ML Maitland","year":"2009","unstructured":"Maitland, M. L. et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 15, 6250\u20136257 (2009).","journal-title":"Clin. Cancer Res."},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","volume":"17","author":"BI Rini","year":"2011","unstructured":"Rini, B. I. et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumours. Clin. Cancer Res. 17, 3841\u20133849 (2011).","journal-title":"Clin. Cancer Res."},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","volume":"24","author":"ML Veronese","year":"2006","unstructured":"Veronese, M. L. et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24, 1363\u20131369 (2006).","journal-title":"J. Clin. Oncol."},{"key":"20_CR24","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1210\/jc.2010-0947","volume":"95","author":"MB Bass","year":"2010","unstructured":"Bass, M. B. et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 95, 5018\u20135027 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"20_CR25","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","volume":"23","author":"CG Willett","year":"2005","unstructured":"Willett, C. G. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23, 8136\u20138139 (2005).","journal-title":"J. Clin. Oncol."},{"key":"20_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-32","volume":"5","author":"SE Deprimo","year":"2007","unstructured":"Deprimo, S. E. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32 (2007).","journal-title":"J. Transl. Med."},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland, M. L., Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J. Natl. Cancer Inst. 102, 596\u2013604 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"20_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-016-3095-6","volume":"78","author":"K Mross","year":"2016","unstructured":"Mross, K. et al. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 78, 405\u2013417 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"20_CR29","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1200\/JCO.2008.21.6655","volume":"27","author":"N Steeghs","year":"2009","unstructured":"Steeghs, N. et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 27, 5094\u20135101 (2009).","journal-title":"J. Clin. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0020-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:01:58Z","timestamp":1684616518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0020-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0020-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,19]]},"assertion":[{"value":"12 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M., E.H., S.W., W.M., J.P., C.D., and P.A.: AbbVie employees and may own stock and\/or options. G.K.L.: Contractor statistician from inVentiv Health Inc. G.F.: Has research funding from AbbVie. R.K.: Has research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant\/advisory board fees from Actuate Therapeutics and XBiotech, and an ownership interest in CureMatch, Inc. M.J.R.: Consultant to AbbVie. D.H.: Has research\/grant funding from Bayer, Lilly, Genentech, Loxo, Pfizer, Amgen, Mirati, Ignyta, Merck, Daiichi Sankyo, Eisai; travel, accommodations, expenses from Mirna, Loxo; consulting or advisory role with Bayer, Baxter, Guidepoint Global; other ownership interests with OncoResponse (founder). The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}